Unspecified Complication of Liver Transplant Clinical Trial
Official title:
Effectiveness of N-acetylcysteine on Preservation Solution During Liver Transplantation
Evaluate the effectiveness of the administration produced antioxidant N-acetylcysteine (NAC), decreasing the incidence of primary graft dysfunction and primary failure. The degree of dysfunction will be monitored by the method of LIMON, metabonomics techniques and according to the latest published validation Liver Transplantation (16 943-949 2010), total billirrubina greater than 10 mg / dl, INR greater than 1.6 in the seventh postoperative day and alanine or aspartate aminotransferase greater than 2000 IU / L in the first seven days. Liver dysfunction is considered, the presence of a transaminase value> 2000 IU / L 1-7 postoperative day or BT> 10 mg / dl or INR> 1.6, both only in the 7th postoperative day (Olthoff et al Liver Transplantation 16,943 -949 2010).
The reason of this study is to evaluate the efficacy of the use of n-acetylcysteine in liver
transplant, by administering it in the perfusion liquid, at the time of extraction of the
liver of the donor to improve the damage caused by ischemia / reperfusion. The dose is 400 mg
in the portal perfusion liquid.
The study included all considered valid and perfused livers. Patients are randomized to
contain no drug or n-acetylcysteine by randomization. Then analyzed using blood tests and in
the receiver and daily during the first seven days post-transplant hepatic dysfunction
parameters, in order to objectify if liver function improves after administration of the
antioxidant (n-acetylcysteine ). Safety assessments were performed with intraoperative
monitoring anesthetic depth, postoperative parameters of liver and kidney function and graft
pathologic examination after perfusion.
;